CD4 and myeloid sarcoma: Importantly, we show that miR-92a was elevated in CD4+ T cells from patients with MS and that miR-92a silencing also effectively promoted both Treg induction and impaired Th17 differentiation in cultured T cells from both HCs and patients with MS.